Companies › Seqker Biosciences
3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Personalized Neoantigen Peptide Vaccine Personalized synthetic long peptides derived from patient-specific tumor neoantigens to st | – | Phase 1 | Solid Tumors | Aug 2027 |
| Poly-ICLC (Hiltonol) TLR3 and RIG-I-like receptor agonist; immune adjuvant | IFIH1, DDX58 | Phase 1 | Solid Tumors; Follicular Lymphoma; Lymphocytic Leukemia | Aug 2027 |
| anti-PD-1 immune checkpoint inhibitor PD-1 checkpoint inhibitor | PDCD1 | Phase 1 | Solid Tumors | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03361852 | Poly-ICLC (Hiltonol) | Phase 1 | Follicular Lymphoma | Oncology | Dec 2026 |
| NCT03219450 | Poly-ICLC (Hiltonol) | Phase 1 | Lymphocytic Leukemia | Oncology | Jul 2027 |
| NCT07002203 | Personalized Neoantigen Peptide Vaccine | Phase 1 | Solid Tumors | Oncology | Aug 2027 |
| NCT07002203 | Poly-ICLC (Hiltonol) | Phase 1 | Solid Tumors | Oncology | Aug 2027 |
| NCT07002203 | anti-PD-1 immune checkpoint inhibitor | Phase 1 | Solid Tumors | Oncology | Aug 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.